

Product Datasheet

GSK-547

Catalog No. **BP-01990** · CAS **2226735-55-1** · Form **free base** · Physical state **solid** · Color **White to off-white** · Version **1.0** · Revision **2026-09-10**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target RIP kinase	Research area Cancer
-----------------------------	--------------------------------

Molecular formula **C₂₀H₁₈F₂N₆O**

Molecular weight **396.3933**

STRUCTURE



DESCRIPTION

GSK547 is a highly selective and potent inhibitor of RIP1.

BIOLOGICAL ACTIVITY

In Vitro

GSK547 (0.1-100000 nM; 24 hours) pretreats L929 cells with recombinant TNFα and zVAD at various doses for 30 min, then cell death is induced with an IC₅₀ of 32 nM after 24 hours.

? GSK547 up-regulates STAT1 signaling in bone marrow-derived macrophages (BMDM).

In Vivo

GSK547 (GSK'547; RIP1i) robustly targets RIP1 in vivo. RIP1 inhibition results in immunogenic macrophage differentiation in pancreatic cancer, leading to adaptive immune activation and tumor protection for pancreatic ductal adenocarcinoma (PDA).

? GSK547 (100 mg/kg/day; fed via food-based dosing; 15-50 days) reduces tumor burden and extends survival compared with mice treated with controls or Nec-1s.

SOLUBILITY

Soluble in DMSO >100 mg/mL

REFERENCES

[1]. Wang W, et al. RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer. Cancer Cell. 2018 Nov 12;34(5):757-774.e7.